Ip Share Price (IPO)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ip Group Plc	LSE:IPO	London	Ordinary Share	GB00B128J450	ORD 2P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-1.60p	-1.77%	88.80p	16,949	10:41:28

Bid Price		Offer Price	High Price	Low Price	Open Price
88.70p		88.90p	91.40p	88.80p	90.40p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
General Financial		-293.70	-27.71		940.5

Related Shares
London Stock Exchange (LSE), Hargreaves Lansdown (HL.), Fandango (FHP), Marechale Capital (MAC)

Ip (IPO) Latest News

Ip News

Date	Time	Source	Headline
16/5/2019	18:21	UKREG	IP Group PLC Withdrawal of resolution from 2019 AGM
03/5/2019	09:38	UKREG	IP Group PLC Appointment of corporate broker
26/4/2019	18:23	UKREG	IP Group PLC LTIP & DBSP awards; DBSP option exercise
18/4/2019	14:54	UKREG	IP Group PLC Annual Financial Report
15/4/2019	11:55	UKREG	Circassia Pharmaceuticals Plc Holding(s) in Company
11/4/2019	09:10	ALNC	IP Group Pleased As Diurnal Gets Positive EMA Feedback For Chronocort
11/4/2019	07:12	RNSNON	IP Group PLC Diurnal positive advice from EMA for Chronocort
26/3/2019	08:26	ALNC	IP Group Reports Growth In Portfolio And Net Asset Value In 2018
26/3/2019	07:01	UKREG	IP Group PLC Final Results
19/3/2019	15:32	UKREG	DeepMatter Group PLC Holding(s) in Company

More Ip News

Ip Takeover Rumours

Ip (IPO) Share Charts

1 Year Ip Chart

1 Month Ip Chart

Intraday Ip Chart

Ip (IPO) Discussions and Chat

Ip Forums and Chat

Date	Time	Title	Posts
17/5/2019	14:19	IP Group - commercialising university technology.	772
11/10/2012	07:43	::: The DIRECT LINE IPO :::	83
08/11/2010	07:59	IP 2 IPO, digging up value, from the boffins.	213
28/7/2010	12:11	IPO- Tracking recent Listings to the LSE	-
21/5/2009	13:40	Anyone have knowledge of PRE - IPO's investments	10

Add a New Thread

Ip (IPO) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
09:41:28	88.80	35	31.08	AT
09:37:59	88.80	4	3.55	AT
09:36:22	88.80	826	733.49	AT
09:36:22	88.80	114	101.23	AT
09:36:22	89.00	38	33.82	AT

View all Ip trades in real-time

Ip (IPO) Top Chat Posts

Date	Subject
22/5/2019 09:20	Ip Daily Update: Ip Group Plc is listed in the General Financial sector of the London Stock Exchange with ticker IPO. The last closing price for Ip was 90.40p. Ip Group Plc has a 4 week average price of 87.50p and a 12 week average price of 85.40p. The 1 year high share price is 145.20p while the 1 year low share price is currently 85.40p. There are currently 1,059,144,595 shares in issue and the average daily traded volume is 551,367 shares. The market capitalisation of Ip Group Plc is £940,520,400.36. Read Full Thread Reply
12/9/2017 21:32	superg1: This looks like a bubble as I've said before figures based on fair value and the market cap of companies. It looks like a false market because due to the heavy backing from the IP group to small companies it artificially inflates the share price of those heavily backed. If you like a solid fund with large holdings keeping the funding going. If they tried to sell up the fair values would capitulate and many of the rl;evenat companies would collapse. Is that about right. I have raised concerns about the chief investment officer who is sat in the board of one Aim company with the FCA. Clearly that company released false news (also reported) since I reported the company share price has dropped over 40%. So do IPO continue to back them and ignore the lies ??? No comment from the company, IPO, FCA or the nomad to date yet they all know about it. We'll see as the relevant company will need cash soon. Read Full Thread Follow Reply
21/6/2017 23:47	p1nkfish: Still have an eye on UBI. Volume peaked up today as someone sold a couple 100k then price recovered. Pretty sure new management will get the 70p+ share price to get their £'s. Read Full Thread Follow Reply
21/6/2017 22:05	p1nkfish: 90% of ivo portfolio value is unlisted. Ivo half year, end of Jan 2017 - "Net assets increased to £472.4 million (FY 2016: £455.9 million), NAV per share £2.93" Original ipo approach was at 307p, could rise to 320p if ipo share price rises to 148p due to 2.1575 conversion ratio. MOST RECENT price equivalent was £2.89p per ivo share - bit of a bargain imho given the potential. Ipo chanced their arm with 3 major ivo shareholders on side. Makes a lot of sense. Read Full Thread Follow Reply
21/6/2017 18:13	p1nkfish: If IPO'S share price ris3s there is upside in ivo to 320p maximum. Every penny extra on Ipo levers up in ivo price. Worth keeping an eye on it. If positions are sorted, valuation might be too if ipo rises in price. Read Full Thread Follow Reply
23/5/2017 07:25	davr0s: Crikey they have been busy. Glad the fund raising is very close to share price. Hopefully it will put some momentum behind this as its not gone very far in last few years. I bought last week so remains to be seen if that was good or bad timing! Read Full Thread Follow Reply
17/1/2016 16:08	eastbourne1982: I've been watching this one recently as I like the business however the valuation is a difficult one to call, given the state of the markets that NAV must have fallen hence the share price drop, one should expect to pay a premium though as the track record is decent, my issue is with the wider markets rather than IP Group itself, if the market irrationally tank these will collapse, on the flip side if the wider markets hold and recover this could be a decent risk / reward trade from around £1.75. Read Full Thread Follow Reply
12/5/2015 07:26	bamboo2: IP Group PLC 12 May 2015 FOR RELEASE ON 12 May 2015 IP Group plc - AGM Statement IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is issuing a statement ahead of its Annual General Meeting which will take place at 2pm today at the Group's offices. This statement provides an update on the Group's progress for the period since 31 December 2014 and replaces the former Q1 Interim Management Statement. Alan Aubrey, Chief Executive of IP Group, said: "I am pleased to report a positive start to 2015, during which the Group has completed a GBP128m equity capital raise and recorded a net increase in the fair value of its portfolio of GBP26m. Overall, our portfolio companies have performed well during the period with several of the quoted companies experiencing an increase in their share prices while, amongst the unquoted companies, Diurnal became the first of the Group's portfolio companies to enter a product into a Phase 3 trial. We remain focused on supporting our portfolio companies and evolving further great ideas into world-changing businesses." Portfolio update As at 8 May 2015, the fair value of the Group's portfolio was GBP385.0m compared to GBP349.9m at 31 December 2014. This represents a net unrealised fair value increase of GBP26.1m during the period, excluding the investments described below. This net fair value increase was primarily driven by the positive share price performance of a number of the Group's quoted companies, including Xeros Technology Group plc (GBP9.5m), hVIVO plc (GBP8.3m) and Applied Graphene Materials plc (GBP3.3m). These were partially offset by total decreases of GBP4.9m in the fair value of the Group's holdings including Azuri Technologies Limited (GBP1.2m) and Ilika plc (GBP1.2m). The Group's portfolio now consists of holdings in 93 intellectual property-based companies. From 1 January 2015 to 8 May 2015, the Group provided incubation, seed and further capital totalling GBP9.1m to 22 portfolio companies. There were no material realisations from the portfolio during the period. Significant developments in the Group's portfolio companies since 31 December 2014 have included: - Diurnal Limited, a spin-out company from the University of Sheffield and in which IP Group holds a 51.7% undiluted beneficial interest, announced in March that it had been granted Orphan Drug designation by the US Food and Drug Administration for its lead product Chronocort(R) , which it has developed to treat the rare disease Congenital Adrenal Hyperplasia. Pivotal Phase 3 trials of Chronocort are due to start later in the year as Diurnal seeks to progress the drug towards market authorisation. In the same month, Diurnal also announced that the first patient had been enrolled onto a Phase 3 trial of its paediatric product, Infacort(R), which it has developed for the treatment of paediatric adrenal insufficiency. The trial is due to be completed by the third quarter of 2016 and represents the first Phase 3 study for Diurnal's portfolio of late-stage products targeted at rare disorders of the endocrine system. - Tissue Regenix Group plc ("Tissue Regenix"), a regenerative medical devices company, announced in January that it had raised GBP20m (before expenses) through a placing of new ordinary shares with both new and existing institutional shareholders. The proceeds will be primarily used for the development and launch of new products, including applications for meniscus repair, ligament repair and heart valve replacement, and to expand its direct salesforce in the US for DermaPure, which is used in the treatment of chronic and acute wounds. The Group committed approximately GBP2.5m to the placing. Tissue Regenix has also announced that it has secured approval from the Medicines and Healthcare Products Regulatory Agency for the first clinical trial of its decellularised tendon device, Orthopure(TM) XT, for the surgical reconstruction of a torn Anterior Cruciate Ligament in the knee, a common sports injury that affects 900,000 people per year globally. - During the period, Xeros Technology Group plc ("Xeros"), the developer of a patented polymer bead cleaning system and in which the Group holds an 11.9% undiluted beneficial interest, announced that additional utility companies in the US had launched energy initiative programmes for customers who commit to reducing their energy consumption through the use of a Xeros Commercial Laundry System. To date, 13 utility companies in the US have launched such incentive programmes. In April, Xeros announced that 61 Forward Channel Partners had signed up to join its North American Commercialisation Programme and also a joint development programme between Xeros and LANXESS Deutschland GmbH to advance the application of Xeros' polymer bead cleaning technology in the leather processing industry. - Finally, Oxford Nanopore Technologies Limited ("Oxford Nanopore"), the Group's largest holding, opened its community-focused access programme - the "MinION Access Programme" - to fresh applications at the beginning of the year while programme participants continued to produce a number of publications in regards to novel applications for the MinION. On 14 and 15 May 2015, Oxford Nanopore will host its "London Calling" conference which is dedicated to nanopore sensing. During this conference, participants in the MinION Access Programme will share their experiences and attendees will learn more about the future of the technology and its applications. In May, IP Group completed its second spin-out in the US and the first from Princeton University. The Group has agreed to provide initial capital of up to $1,500,000 for a significant minority stake in Uniformity Labs Inc., which develops optimised feedstock powders for 3D printing. The initial capital will be provided in tranches subject to successful attainment of commercial and technical milestones. Board changes In March, the Group announced that Mike Humphrey was to become Non-executive Chairman with effect from the conclusion of the Group's Board meeting held on 24 March 2015. Mr Humphrey, who joined the IP Group Board in 2011 and was appointed Senior Independent Director in that same year and Chairman of the Remuneration Committee in 2014, replaced Dr Bruce Smith CBE, who stepped down after 12 years on the Board. With effect from that same date, Doug Liversidge CBE, who joined the Board in 2014, assumed the role of Senior Independent Director and Jonathan Brooks, a member of the Board since 2011, became Chairman of the Remuneration Committee. The Nomination Committee is actively searching for an additional Non-executive Director for the Board and will make an announcement once this process has been completed. Balance sheet update In March, the Group completed an equity capital raise of GBP128m (before expenses). This has left the Group well positioned to continue to increase its overall rate of capital deployment into its existing maturing portfolio as well as into new early stage opportunities, both in the UK and the US. At 8 May 2015, the Group had cash of GBP212m, a diversified portfolio valued at GBP385m and net assets of GBP672m, representing 125p per share. Excluding intangible assets and the Oxford Equity Rights asset, the Group's "hard" net assets were GBP600m or 111p per share. Read Full Thread Follow Reply
11/3/2015 15:36	hjs: Todays drop in share price is very strange. Who would buy at 225 when they can buy today at 220? Did the placing brokers got it wrong? Normally a small discount would amount to share price moving higher instead in IPO's case, it has gone below issue price of 225. Read Full Thread Follow Reply
19/2/2014 15:16	praipus: Buy FIP who get .446 of a NEW IPO share for each FIP share I've noticed a few days on the trot now the FIP share price lags the IPO share price move when in fact they should be moving in lock step....as usual double check DYOR etc :-) "Under the terms of the Offer, Scheme Shareholders will be entitled to receive 0.446 of a New IP Group Share for every Scheme Share held." http://uk.advfn.com/news/UKREG/2014/article/60763463 Read Full Thread Follow Reply
13/2/2014 13:30	malhashemi: If this is the craziness that is currently out there, then IP Group should milk this for all that it can. It should put forward at least one or two of its incubated businesses for IPO before summer and cash in on this mania. If they pull this off, then good luck to them. There is no shame in taking advantage of this mania.This mania will not last. Look through the history of the markets.. Any window of time that saw IPOs rising by 300% or more was followed by a correction ( hence my reference to the lastminute.com IPO ). With all due respect to anyone who maybe have bought Actual Experience in the market today at 200p or above, what on earth do you think the share price will do next when you paid 4 times the IPO price ? Double again by next week to 400p? And what exactly would cause it to that. So much "good news" is already in the price when it goes up fourfold in one day there is no room for positive upside left... Read Full Thread Follow Reply

Ip share price data is direct from the London Stock Exchange

Your Recent History

LSE

IPO

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190522 10:00:39